Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples